Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Plain-language summary

This study compared patient-reported outcomes for Rimegepant versus Triptans in people with migraine, using data from the 2023 US National Health and Wellness Survey. Survey participants aged 18 and over with a physician diagnosis of migraine who were then using oral Rimegepant or a Triptan were included. It was a non-phase study that has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Pfizer

Intervention

Rimegepant, Triptans

Start date

10/10/2024

Estimated completion

11/20/2024

Countries

United States

Related genes

Locations

• New York, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Participated in 2023 NHWS in the US
* Consented to the anonymous use of their data for research purpose
* Aged 18 or older
* Self-reported a diagnosis of migraine by physician
* Currently on rimegepant or triptan (via oral route) at the time of the survey

Exclusion Criteria:

\- Currently on both rimegepant and triptans at the time of the survey